GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » Net Issuance of Debt
中文

Allergy Therapeutics (Allergy Therapeutics) Net Issuance of Debt

: $-1.05 Mil (TTM As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Allergy Therapeutics's net issuance of debt for the six months ended in Dec. 2023 was $-33.33 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.05 Mil.


Allergy Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Allergy Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.83 1.54 -0.19 -1.18 31.62

Allergy Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.61 -0.65 32.29 -33.33

Allergy Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics (Allergy Therapeutics) Business Description

Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics (Allergy Therapeutics) Headlines